NanoThera Summit 2025: An event that consolidates Valencia as a key hub for innovation in nanotherapies and advanced Therapies Valencia, September 2025 The inaugural edition of NanoThera Summit has been a complete success, establishing Valencia as a global benchmark in the fields of nanotherapies, advanced drug delivery, and gene therapy.
Curapath is gearing up for a busy season of innovation, networking, and collaboration. Over the next few months, our team will be present at some of the world’s leading biotech and pharmaceutical conferences, connecting with partners, sharing insights, and showcasing our latest advances in drug delivery technologies. Here’s where you’ll
Curapath has entered into an exclusive license agreement with Calusa Bio, LLC, further strengthening its PEG alternative toolbox with a novel and differentiated technology. This strategic addition enhances our ability to advance PEG-free delivery systems for biologics, peptides, and nucleic acids in next-generation therapies. By combining Curapath’s expertise in PEG-free
VALENCIA, SPAIN, SEPTEMBER 2, 2025 At Curapath, our mission has always been to push the boundaries of non-viral drug delivery. Today, we are proud to announce a strategic partnership with Cayman Chemical that will make our proprietary PEG-free shielding lipids more accessible to researchers worldwide. Through Cayman’s extensive global distribution
The CDMO journey is never just operational, it’s human. In this 7-question Q&A, Philippe Clavel, CEO of Curapath, shares his reflections on the first half of 2025: what we’ve achieved, what we’ve learned, and what it takes to keep growing while staying grounded in purpose and people. This interview goes beyond
VALENCIA, COMUNIDAD VALENCIANA, SPAIN, July 1, 2025 /EINPresswire.com/ — Macro Biologics, Inc. , a US-based company (Carlsbad, Carlifornia) at the intersection of materials science and biotechnology, develops innovative products for healthcare and beyond. Curapath, a CDMO based in Spain, specializes in advanced polymer and lipid synthesis, novel excipients, and nanoparticle formulations. The two
Paterna, May 9, 2025 – Curapath, a global life sciences company specializing in the custom design, development, and manufacturing of advanced drug delivery systems, yesterday welcomed an institutional visit from Felipe Carrasco, Regional Secretary of Industry, Commerce, and Consumer Affairs, and Rafael Escamilla, Director of External Relations at IVACE, at
February 24, 2025, Valencia, Spain – In a significant step towards strengthening its presence in the biotechnology and pharmaceutical sector, CURAPATH has been officially accepted as a member of the Innovation Club of the Valencian Community (CiCV) https://www.clubinnovacioncv.com/. This event took place at the recent General Assembly of the
November 21, 2024, Valencia, Spain, At Curapath, we believe that a fair, inclusive, and diverse workplace is the foundation for innovation and collective well-being. In alignment with this belief, we are proud to announce the official approval and publication of our Gender Equality Plan (GEP), a key milestone that reinforces
Recognized as one of Europe’s Leading Drug Delivery and Manufacturing Companies by Euro Insights Care, Curapath continues to set benchmarks in the field of advanced non-viral drug delivery systems. This accolade underscores the company’s pivotal role in shaping innovative solutions, particularly in polymer and lipid-based therapies. Curapath specializes in the
